We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Level up your trading with our powerful tools and real-time insights all in one place.
The current EX9 market cap is 9.77B. The company's latest EPS is USD 1.8625 and P/E is 20.25.
| Year End January 02 2025 | 2021 | 2021 | 2022 | 2023 | 2025 |
|---|---|---|---|---|---|
| USD ($) | USD ($) | USD ($) | USD ($) | USD ($) | |
| Total Revenue | 987.54M | 1.43B | 1.61B | 1.83B | 2.17B |
| Operating Income | 110.06M | 286.67M | 201.48M | 170.89M | 656.29M |
| Net Income | 111.78M | 231.06M | 182.28M | 207.77M | 521.27M |
| Year End January 02 2025 | 2021 | 2021 | 2022 | 2023 | 2025 |
|---|---|---|---|---|---|
| USD ($) | USD ($) | USD ($) | USD ($) | USD ($) | |
| Total Assets | 2.14B | 2.62B | 3.07B | 2.94B | 2.95B |
| Total Liabilities | 258.22M | 405.62M | 583.06M | 678.45M | 703.49M |
| Total Equity | 1.88B | 2.21B | 2.49B | 2.26B | 2.24B |
| Year End January 02 2025 | 2021 | 2021 | 2022 | 2023 | 2025 |
|---|---|---|---|---|---|
| USD ($) | USD ($) | USD ($) | USD ($) | USD ($) | |
| Operating | 208.98M | 400.8M | 362.61M | 333.32M | 699.97M |
| Investing | -131.22M | -42.88M | -524.41M | -26.96M | -116.78M |
| Financing | -25.13M | -14.8M | 586k | -546.05M | -628.81M |
| Market Cap | 9.77B |
| Price to Earnings Ratio | 20.25 |
| Price to Sales Ratio | 4.87 |
| Price to Cash Ratio | 48.56 |
| Price to Book Ratio | 4.7 |
| Dividend Yield | - |
| Shares Outstanding | 279.88M |
| Average Volume (1 week) | 261 |
| Average Volume (1 Month) | 541 |
| 52 Week Change | 61.89% |
| 52 Week High | 38.36 |
| 52 Week Low | 18.485 |
| Spread (Intraday) | 1.23 (3.46%) |
| Company Name | Exelixis Inc Dl 01 |
| Address |
251 little falls drive wilmington, delaware 19808 |
| Website | https://www.exelixis.com |
| Industry | biological pds,ex diagnstics (2836) |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: 1-888-992-3836 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
